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Abstract
The TSH receptor (TSHR) comprises an extracellular leucine-rich domain (LRD) linked by a hinge region to the
transmembrane domain (TMD). Insight into the orientation of these components to each other is required for
understanding how ligands activate the receptor. We previously identified residue E251 at the LRD-hinge junction as
contributing to coupling TSH binding with receptor activation. However, a single residue cannot stabilize the LRD-hinge
unit. Therefore, based on the LRD crystal structure we selected for study four other potential LRD-hinge interface charged
residues. Alanine substitutions of individual residues K244, E247, K250 and R255 (as well as previously known E251A) did not
affect TSH binding or function. However, the cumulative mutation of these residues in varying permutations, primarily
K250A and R255A when associated with E251A, partially uncoupled TSH binding and function. These data suggest that
these three residues, spatially very close to each other at the LRD base, interact with the hinge region. Unexpectedly and
most important, monoclonal antibody CS-17, a TSHR inverse agonist whose epitope straddles the LRD-hinge, was found to
interact with residues K244 and E247 at the base of the convex LRD surface. These observations, together with the
functional data, exclude residues K244 and E247 from the TSHR LRD-hinge interface. Further, for CS-17 accessibility to K244
and E247, the concave surface of the TSHR LRD must be tilted forwards towards the hinge region and plasma membrane.
Overall, these data provide insight into the mechanism by which ligands either activate the TSHR or suppress its constitutive
activity.
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Introduction
The glycoprotein hormone receptor (GPHR) structure consists
of three distinct components. Like all members of the G protein
coupled receptor (GPCR) family, a serpentine membrane
spanning domain is responsible for communicating with the
intracellular signaling mechanism. Based on the solved crystal
structure of this component in other rhodopsin-like GPCR family
members [1–4], molecular modeling of the GPHR transmem-
brane domain (TMD) provides a reasonable structural represen-
tation. The second GPHR domain, entirely extracellular and
comprising the major ligand binding site, consists of leucine-rich
repeats (approximately 240 amino acid residues after removal of
the signal peptide). The structure of this leucine-rich repeat
domain (LRD) is even more clearly established than that of the
TMD, with crystal structures available for both the FSH- [5] and
TSH- [6] receptors. The structure of the third GPHR component,
a hinge region linking the LRD to the TMD (approximately 100–
150 amino acid residues in different family members), is unknown.
Insufficient homology to other known proteins precludes reliable
molecular modeling. At least in the case of the TSHR, the hinge
region contains a portion of the ligand binding site [7–10].
Without insight into the relative orientation to one another of
the GPHR components (LRD, hinge and TMD) it is not possible
to understand, even from ligand-LRD crystal structures [5,6], the
mechanism by which ligand binding triggers intracellular
signaling. All three GPHR components have not been crystallized
as a unitary structure. Consequently, GPHR models have varied
widely. The tubular, slightly curved LRD has been projected to lie
horizontally, parallel to the plasma membrane [11], vertical to the
plasma membrane [5,12,13], or at an angle to the plasma
membrane [13,14].
Recently, an inadvertent PCR cloning artifact encoding an
E251K mutation in the TSHR LRD revealed reduced sensitivity
to TSH stimulation despite normal high affinity TSH binding
[15]. Residue E251 is situated at the base of the TSHR LRD
(amino acid residues 22–260) near the junction of the LRD with
the hinge region (Fig. 1A). Based on the proximity of residue E251
to the TSHR hinge region, together with the E251K mutation
partially uncoupling ligand binding from signal transduction, we
hypothesized that residue E251 projects into the hinge region.
Uncoupling of TSH binding from TSHR signaling occurs with an
E251K, but not with an E251A mutation [15]. This information
suggests that E251K does not form a salt bridge with hinge
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31973residues. Rather, an E to K mutation increases the length and
bulkiness of the projecting side-chain and could disrupt the normal
LRD-hinge interface. Toleration of an E251A mutation is
consistent with a minimal (single methyl) side-chain and
stabilization by adjacent residues. The present study was based
initially on the premise that amino acid residue E251 alone could
not stabilize the attachment of a very large LRD to the hinge
region. We, therefore, sought other TSHR LRD amino acid
residues that could contribute to the stability of an LRD-hinge
structural unit. These mutations yielded unanticipated information
on the epitope of monoclonal antibody CS-17, a TSHR inverse
agonist [16], providing insight into the structure of the receptor.
Results
Strategy for TSHR LRD residue mutations
Because multiple amino acids are likely to stabilize the TSHR
LRD-hinge junction, we examined the TSHR LRD crystal
structure for other potential residues adjacent to E251 that could
interface with the hinge region and that do not contribute to the
TSH binding site [17,18]. We noted the LRD C-terminal base to
be rich in additional charged amino acids, namely K244, E247,
K250 and R255 (Fig. 1B and 1C). To study these residues, we
chose a progressive, cumulative alanine substitution strategy.
Alanine mutations would eliminate potential salt bridges without
the major effect on protein conformation; as mentioned above
E251A, unlike E251K, had no effect on TSH induced signal
transduction [15]. By progressively ‘loosening’ the LRD-hinge
interface with alanine substitutions (analogous to strands in a
rope), we hypothesized that we would, at least partially, uncouple
TSH binding from receptor activation.
Effect of charged amino acid mutations at the TSHR LRD
base on signal transduction
Compared with the wild-type TSHR, alanine substitutions for
single TSHR LRD residues K244, E247, K250, E251 and R255
did not significantly alter the sensitivity of the intracellular cAMP
response to TSH stimulation (effective concentrations required for
50% activation; EC50)(Fig. 2A). Similar data for E251A have been
reported previously [15]. For comparison with the E251A
mutation, the previously published effect of an E251K mutation
on the cAMP response to TSH stimulation is also depicted
(Fig. 2A, red line) [15]. The cAMP data in this and subsequent
figures are shown as a percentage of the absolute cAMP attained,
with the latter values provided in the figure legends.
With no single amino acid mutations causing significant
functional changes, we next examined dual mutations, using
E251A as a template because of the known importance of the
E251K mutation. The EC50 for TSH stimulation of E251,244A
was similar to that of the wild-type TSHR (representative experiment
shown in Fig. 2B). Small increases in the EC50 for TSH (reduced
sensitivity) were observed with the three other dual mutations
(E251A,K247A; E251A,K250A; and E251A,R255A)(Fig. 2B). With
such small changes we studied these cell lines repeatedly. Combining
thedataforsixexperiments,theshifttotherightintheEC50withthe
E251A,K250A and E251A,R255A dual mutations was significant
compared to the wild-type TSHR (Fig. 3). We next tested triple
mutations using TSHR E251A,K250A as a template. All three
Figure 1. Schematic representation of the three components of the TSHR. The leucine-rich repeat domain (LRD) is linked to the serpentine
transmembrane domain (TMD) by the hinge region. The crystal structure of the TSHR LRD has been solved [6](Protein Data Base 3G04) and is shown
using FirstGlance in Jmol (http://molvis.sdsc.edu/fgij/). The TMD structure can be modeled with reasonable confidence from the crystal structureso f
other Group A, rhodopsin-like, GPCR members [1–4]. The structure of the intervening hinge region is totally unknown. A. Depiction of all three
components. TSH binds largely to the LRD with a smaller contribution to the binding site by the hinge region. Figure 1A is a modification of Figure 6
in Ref. [15]. B. Side view of TSHR LRD. Charged residues at the C-terminal base of the LRD are indicated by the yellow halos. C. Inferior aspect of the
TSHR LRD.
doi:10.1371/journal.pone.0031973.g001
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and E251A,K250A,R255A) demonstrated small, but significant,
reductions in sensitivity to TSH stimulation (Figs. 2C and 3).
When all five of the selected charged residues (K244, E247,
K250, E251 and R255) were converted to alanine (for brevity
termed ‘V’), the TSH EC50 was 13-fold higher than for the wild-
Figure 2. Functional effects of mutating charged residues at the C-terminal base of the TSHR LRD, singly and in combination. Unless
indicated otherwise, all mutations were to alanine. CHO cells stably expressing TSHR with the indicated mutations, as well as the wild type TSHR, were
incubated for 1 h in the indicated concentrations of TSH and intracellular cAMP measured (Methods). In each panel, the points represents the mean
6 range of cAMP values in duplicate wells of cells. Values are expressed as a percentage of the maximal cAMP attained. The TSH effective
concentrations required for half-maximal stimulation (EC50) in these representative experiments are indicated by the horizontal dashed line. The
mean values and statistical analysis of data from multiple experiments are depicted in Figure 3. Panel A. Single mutations to alanine of charged
residues at the base (C-terminus) of the TSHR LRD. For comparison, the previously published effect of an E251K mutation on the cAMP response to
TSH stimulation [15] is shown in red. In the experiment shown, with basal cAMP levels of 0.8–1.3 pmoles per well of cells, mean maximum cAMP
values attained were 60.5 (wild-type), 58.7 (K244A), 52.2 (E247A), 39.4 (K250A), 49.9 (E251A) and 66.1 (R255A) pmoles per well of cells. Panel B. Double
mutations to alanine of charged residues at the C-terminus of the TSHR LRD. In the experiment shown, with basal cAMP levels of 0.5–0.8 pmoles per
well of cells, mean maximum cAMP values were 60.5 (wild-type), 52.1 (E251,244A), 51.7 (E251A,K247A), 48.2 (E251A,K250A), and 54.7 (E251A,R255A)
pmoles per well of cells. Panel C. Triple mutations to alanine of charged residues at the base of the TSHR LRD. In the experiment shown, with basal
cAMP levels of 0.9–1.4 pmoles per well of cells, mean maximum cAMP values were 69.3 (wild-type), 57.9 (E251A,K250A,K244A), 55.2
(E251A,K250A,E247A) and 53.5 (E251A,K250A,R255A) pmoles per well of cells. Panel D. Combination of four (IV) and five (V) mutations to alanine
of charged residues at the base of the TSHR LRD. In the experiment shown, with basal cAMP levels of 0.6–1.0 pmoles per well of cells, mean
maximum cAMP values were 69.3 (wild-type), 42.9 (K244A,E247A,K250A,R255A), and 33.4 (K244A,E247A,K250A,E251A,R255A) pmoles per well of cells.
Panel E. Single mutations of K244, E247, K250 and R255 to residues with an opposite charge. In the experiment shown (representative of three), with
basal cAMP levels of 0.7–1.4 pmoles per well of cells, mean maximum cAMP values were 27.3 (wild-type), 31.7 (K244E), 35.8 (E247K), 34.6 (K250E) and
34.5 (R255E) pmoles per well of cells.
doi:10.1371/journal.pone.0031973.g002
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ANOVA)(Figs. 2D and 3). Because E251A was common to all
prior multiple mutations (double, triple and five), we examined the
role of the four other residues without the E251A mutation
(K244A,E247A,K250A,R255A), termed ‘IV’. This receptor, too,
had reduced sensitivity to TSH stimulation, with an EC50 of
0.6760.05 mU/ml, approximately three-fold higher than for the
wild-type TSHR (p,0.05, ANOVA; Fig. 2D and 3). None of the
foregoing single and multiple alanine substitutions had a
significant effect on constitutive, ligand-independent TSHR
activity (range of values described in the Figure legends). As with
the alanine substitutions, individual mutations of the four amino
acids studied to residues of the opposite charge, namely K244E,
E247K, K250E and R255E, did not significantly alter the TSH
EC50 for cAMP generation (Fig. 2E). In contrast, as shown in
Figure 1A, an E251K mutation reduces sensitivity to TSH
stimulation by approximately one order of magnitude. None of the
charge inversion mutations, including E251K, led to an alteration
in constitutive, ligand-independent TSHR activity (range of values
in the legend to Fig. 2E).
Because TSHR mutants IV and V exhibited partial uncoupling
of signal transduction despite normal, high affinity TSH binding
(see below), we examined whether a similar effect occurred with
M22, a human monoclonal thyroid stimulating autoantibody [19].
Information from this study was potentially limited because, unlike
TSH whose binding is unaffected by these receptor mutants, the
crystal structure reveals R255 to be an M22 contact residue, and
an R255A mutation is reported to reduce the M22 binding affinity
5-fold with a proportionate decrease in signal transduction [6]. Of
note, TSHR residues K244, R247, K250 and E251 are not part of
the M22 epitope. Relative to the wild-type TSHR, M22 had
minimal activity with TSHR mutants IV and V in terms of cAMP
generation (Fig. 4). The implications of this finding are discussed
below (Discussion).
TSH binding affinity to receptors with reduced sensitivity
to TSH stimulation
Reduced sensitivity to TSH stimulation in TSHR mutants could
be caused by a decrease in TSH binding affinity or by partial
uncoupling of ligand binding and signal transduction. We focused
on the TSHR with 4 and 5 alanine substitutions (IV and V) which
had clearly decreased sensitivities in their functional responses to
TSH. These reduced sensitivities were not attributable to lower
TSH binding affinity. Scatchard analysis of TSH competition for
125I-TSH binding in four separate experiments yielded Kds for
TSHR IV and V of 0.6760.23 and 1.3460.65 mU/ml TSH
(mean 6 SE), respectively, relative to a Kd of 2.4060.30 mU/ml
TSH for the wild-type TSHR studied in parallel wells of cells
(Table 1). Indeed, the TSH binding affinity for TSHR IV was
significantly higher than for the wild-type TSHR (p=0.004;
Student’s test). However, in our experience, with varying levels of
TSHR expression, such comparisons are imprecise. In particular,
Figure 3. Summary and comparison of the sensitivities to TSH stimulation in all groups with alanine substitutions. The numbers
besides bars indicate the amino acid residues that were mutated to alanine. Each bar represents the mean+S.D. of the EC50s for TSH stimulation of
cAMP generation. The number of experiments is indicated in parentheses. Statistical comparison of each groups vs. the wild-type TSHR (wt) was
performed by One-way ANOVA.
doi:10.1371/journal.pone.0031973.g003
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underestimate TSH binding affinity [20]. The important conclu-
sion, however, is that independent of the wild-type TSHR, the Kd
values for the TSHR IV and V mutants reflect high TSH binding
affinities and, when associated with reduced sensitivity to TSH
stimulation, indicate partial uncoupling between ligand binding
and signal transduction.
Flow cytometric determination of TSH receptor
expression level
Flow cytometry was performed on CHO cells stably expressing
the wild-type and mutant TSHR using a panel of three different
monoclonal antibodies (mAb) with different epitopes. The epitopes
for two mAb are far removed from the LRD mutations,
recognizing C-terminal portions of the hinge region close to its
insertion into the plasma membrane. Thus, the epitopes for mAb
4C1 and 2C11 include residues 381–384 and 355–358, respec-
tively [21]. In general, as measured by the latter two mAb, the
level of cell surface expression progressively diminished in
proportion to the number of TSHR mutations (Fig. 5). It is
noteworthy that despite the low fluorescence signals for TSHR IV
and V both mutants exhibited strong cAMP responses to TSH
(Fig. 2D legend) and maximum
125I-TSH binding values (Table 1).
This disparity can be explained by lesser flow cytometry sensitivity
(higher threshold for detection) relative to the more sensitive
functional and ligand binding procedures.
A serendipitous finding, the most important of the present
study, emerged when we included mAb CS-17, a TSHR inverse
agonist [16], in parallel tubes with the other two mAb. CS-17 was
generated by immunization with the TSHR LRD and the N-
terminal portion of the hinge region (amino acid residues 1–289).
Relative to mAb 4C1 and 2C11, CS-17 recognized less well all
TSHR mutants that included the K244A and E247A mutations
within the LRD (Fig. 5).
TSHR residues K244 and E247
Because these two residues cannot be both water accessible
(required to be part of the antibody epitope) and buried within the
TSHR hinge region, such information had potentially important
implications for the orientation of the LRD relative to the hinge
region (see Discussion). In our earlier studies on the functional
effects of alanine substitutions on the cAMP response to TSH
(Fig. 2), we did not examine the combination of TSHR residues
K244 and E247 independently of the other three charged residues
(K250, E251 and R255). We, therefore generated a TSHR with
both K244 and E247 converted to alanine. The EC50 of this
mutant for TSH stimulation of cAMP generation was not different
to that of the wild-type TSHR (Fig. 6). Moreover, in the receptor
with all five charged residues converted to alanine (receptor ‘‘V’’),
whose sensitivity to TSH stimulation is reduced (Figs. 2D and 3),
reversion of residues 244 and 247 back to the wild-type (A244K or
A247E) did not lessen this degree of insensitivity (Fig. 6). These
data indicate that TSHR residues K244 and E247 at the base of
the LRD do not have a significant functional role in coupling TSH
binding with signal transduction.
Discussion
The goal of the present study was to examine the role of four
charged amino acid residues adjacent to E251 at the base (C-
terminus) of the TSHR LRD in coupling TSH binding and signal
transduction. As is evident from Figure 1B and 1C, our choice of
residues to study was limited. Other non-charged residues,
probably hydrophobic, are almost certainly involved. Neverthe-
less, focusing on the charged residues selected for mutation,
individual, dual or triple alanine substitutions of amino acid
residues K244, E247, K250 and R255, as well as previously
reported E251 [15], had no or a small effect on the sensitivity to
TSH stimulation of intracellular cAMP generation. Yet replace-
Figure 4. Thyroid stimulating monoclonal autoantibody M22
stimulation of TSHR variants. CHO cells stably expressing the wild-
type TSHR and the TSHR with four residues (K244,E247,K250,R255) and
five residues (K244,E247,K250,E251,R255) converted to alanine, termed
‘IV’ and ‘V’ respectively, were incubated for 1 h in the indicated
concentrations of M22 and intracellular cAMP measured (Methods).
Each point represents the mean 6 range of cAMP values in duplicate
wells of cells. The experiment shown is representative of three separate
experiments. The very low responses of TSHR-IV and TSHR-V preclude
determination of the M22 EC50’s, so absolute cAMP values are shown.
The M22 EC50 for the wild-type TSHR is indicated by the horizontal
dashed line. In all other experiments in which there was a robust cAMP
response, for better visualization of the EC50, cAMP values were
normalized to 100% of the maximal value attained.
doi:10.1371/journal.pone.0031973.g004
Table 1. TSH binding to TSHR with four and five charged
residues mutated to alanine.
Kd
(TSH mU/ml)
Mean ± SE
125I-TSH Bound
(% of total cpm)
125I-TSH Bound
(% of wild-type)
Wild-type 2.4060.30 29.161.1 100
Mutation
combination
‘IV’
K244A
E247A
K250A
(-)
R255A
0.6760.23* 16.463.0 55.869.3
Mutation
combination
‘V’
K244A
E247A
K250A
E251K
R255A
1.3460.65 11.061.8 37.565.8
TSHR IV (K244A, E247A, K250A, R255A), TSHR V (K244A, E247A, K250A, E251A,
R255A) and the wild-type TSHR stably expressed in CHO cell monolayers were
incubated for 4 h at room temperature in buffer containing
125I-TSH
supplemented with the indicated concentrations of unlabeled TSH (Methods).
Data from four separate experiments are expressed as the mean 6 S.E.M. of
radioactivity bound as a percentage of total radioactivity added per well
(typically ,30,000 cpm).
*p=0.004, Student’s t-test.
doi:10.1371/journal.pone.0031973.t001
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recapitulated the functional effect of the single E251K mutation. A
TSHR with four alanine substitutions, leaving E251 unchanged
(mutant receptor ‘‘IV) also led to partial uncoupling of TSH
binding and signal transduction, but not to the same extent as in
TSHR ‘‘V’’. Thus, the E251A mutation (ineffective on its own) has
a synergistic effect when combined with the lesser effect caused by
alanine substitutions of the other four charged residues. Inciden-
tally, although unrelated to our present study of ligand-mediated
TSHR activation, ligand-independent (constitutive) TSHR activity
was unaltered in the receptor mutants presented herein, as well as
in receptors in which the selected charged amino acid residues
were substituted with residues of the opposite charge.
The novel information provided by our present data is that, (i)
E251 is dominant among the five charged residues selected for
study and, (ii) when mutated as a group, adjacent amino acids,
particularly K250 and R255 do, indeed, contribute to coupling
TSH binding and signal transduction. These findings support the
hypothesis that multiple amino acids are involved in stabilizing the
TSHR LRD-hinge complex. Each alanine substitution, particu-
larly of residue E251, loosens this attachment, analogous to
progressively severing the strands on a rope. That the dual alanine
substitution of K244 and E247, when added to the triple mutation
of K250, E251 and R255, reduces the sensitivity to TSH
stimulation despite K244 and E247 contributing to the CS-17
epitope (see below) is puzzling but could be explained by an
allosteric effect on other residues at the LRD-hinge junction.
Recent mutagenesis data provide further strong evidence that
amino acid residues at the junction of the TSHR LRD and hinge
regions further downstream to the residues studied in the present
report, contribute to signal transmission following TSH binding
[22].
Figure 5. Cell surface expression by TSHR mutants determined by flow cytometry. TSHR mutants were stably expressed in CHO cells. The
numbers below each bar indicate the TSHR residue mutated without, for simplicity, the specific amino acid substitution. Each cell line was tested with
the three indicated monoclonal antibodies. Geometric mean fluorescence for each is net after subtraction of fluorescence obtained for each mAb
with control, untransfected CHO cells (9–10 fluorescence units). Backgrounds with normal IgG controls for each mutant cell line were ,2–6
fluorescence units. The vertical arrows indicate the low fluorescence observed with mAb CS-17 relative to the other two mAb, all such cell types
involving mutation of residue K244 and/or E247.
doi:10.1371/journal.pone.0031973.g005
Figure 6. TSHR residues affecting monoclonal antibody CS-17
binding do not alter the cAMP response to TSH stimulation.
CHO cells stably expressing TSHR with the indicated mutations, as well
as the wild type TSHR, were incubated for 1 h in the indicated
concentrations of TSH and intracellular cAMP measured (Methods).
Each point represents the mean 6 range of cAMP values in duplicate
wells of cells. Values are expressed as a percentage of the maximal
cAMP attained. The TSH effective concentration required for half-
maximal stimulation (EC50) is indicated by the horizontal dashed line.
‘‘V’’ represents a receptor with mutation to alanine of five charged
residues (K244,E247,K250,E251 and R255). On this background, the
alanine mutations of residue 244 or 247 were reverted to the wild-type.
In the representative experiment (of four) shown, with basal cAMP
levels of 0.2–0.4 pmoles per well of cells, mean maximum cAMP values
were 19.2 (wild-type), 20.4 (K244A, E247A), 22.8 (‘‘V’’,A244K) and 19.5
(‘‘V’’,A247E) pmoles per well of cells.
doi:10.1371/journal.pone.0031973.g006
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17 provides the most interesting and important information in our
study. All TSHR that we investigated with either K244 or E247
replaced by alanine were recognized poorly by mAb CS-17
relative to two other antibodies with epitopes further downstream
than the mutated amino acids presently studied. These data
provide strong evidence that TSHR K244 and E247 contribute to
the CS-17 epitope. Support for this conclusion is that from the
TSHR LRD crystal structure, K244 and E247 are located on the
same plane as, and very close to, other residues previously
identified in the CS-17 epitope, namely Y195 [23], N198 and
T200 [14](Fig. 7). Further evidence suggests that CS-17 also
interacts with residues T273 and R274 in the TSHR hinge region
[14], the structure of which has not been solved.
The interaction of mAb CS-17 with TSHR residues K244 and
E247 indicates that the latter are water accessible and, therefore,
cannot contribute significantly to the LRD-hinge interface. Based on
the crystal structure of the TSHR LRD [6], for E251 (and possibly
K250 and R255), but not K244 and E247, to be at the LRD-hinge
interface, itisa reasonablededuction thatthe LRD istilted forwards,
with its concave, ligand binding surface inclined towards the hinge
region and plasma membrane (Fig. 7). The present experimental
data support the previous theoretical concept of the relationship
between the TSHR LRD and the hinge region [13,15].
Although the present data address the action of TSH, Figure 7
schematically depicts the binding of the monoclonal thyroid
stimulating autoantibody (TSAb) Fab M22. Despite M22 and
TSH both interfacing with overlapping regions on the concave
surface of the TSHR LRD, the orientation of the two ligands is very
different. TSH and FSH are elongated molecules that bind
transversely to the LRD, partially wrapping around the LRD as in
a hand clasp [5,24]. M22 on the other hand binds in a more
perpendicular manner to the LRD [6]. Further, thyroid stimulating
autoantibodies [25] including M22 [26], but not TSH [27,28],
preferentially recognize the extracellular domain of the TSH
holoreceptor rather than the identical extracellular domaintethered
to the plasma membrane by a flexible glycosylphosphatidyl inositol
(GPI) anchor. These data provide strong evidence that TSAb access
to the TSHR holoreceptor is partially restricted (steric hindrance)
and suggest a mechanism by which TSAb activate the receptor.
Completion of TSAb binding to a partially obscured epitope could
lead to torsion of the receptor transmitted via the hinge region and
extracellular loops to a shift in the relative positions of the
transmembrane helices. The present data suggesting that the
TSHR LRD inclines forward towards its concave surface provides
additional support for this concept and is also consistent with TSH
making contact with both the LRD and hinge region [7–10].
The almost total inability of M22 to activate TSHR ‘IV’ and ‘V’
(Fig. 4) requires comment. Both receptors contain an R255A
substitution, previously reported to reduce M22 binding affinity 5-
fold with a proportionate reduction in cAMP generation [6]. As
such, these data do not suggest uncoupling between ligand binding
and signal transduction. In contrast, the near total abrogation of a
functional response to M22 by TSHR-IV and -V support the
concept that these combined mutations uncouple, at least in part,
signal transduction for TSAb as well as for TSH. In the crystal
structure of the M22-TSHR LRD complex, residue R255 is at the
extreme periphery of the M22 epitope, with only part of the R255
side-chain contacting the antibody. A major portion of R255 is
exposed. Because the crystal structure extends to residue T257 and
the hinge is entirely absent, R255 could interface with both M22
and the hinge region. It should also be recalled that the shed A-
subunit (essentially the LRD) is the likely immunogen for the
generation of pathogenic TSAb in Graves’ disease [25,26,29].
Figure 7. Schematic representation of the orientation of the TSHR LRD to the hinge region. The crystal structure of the TSHR LRD in
complex with the M22 human monoclonal stimulating autoantibody Fab [6](Protein Data Base 3G04) is shown as a ribbon diagram using FirstGlance
in Jmol (http://molvis.sdsc.edu/fgij/). For mAb CS-17 to contact TSHR residues K244 and E247 on its convex surface, these residues cannot be buried
in the hinge region and the TSHR LRD is, therefore, likely to tilt forward towards its concave face, as shown by the arrow. Obviously, the M22 IgG
molecule including a second Fab and an Fc is even larger than the M22 Fab and would be even more susceptible to steric hindrance, with completion
of its binding by forcing out water molecules leading to torsion of the LRD vis-a-vis the hinge region. It should be noted, however, that the M22 Fab
alone can activate the TSHR [19]. For simplicity, TSHR amino acid residues K250, E251 and R255 interfacing with the hinge region are omitted and are
better visualized in Figure 1. Of note, in Figure 1C (inferior view of the LRD base) these three residues lie towards one pole, with CS-17 epitope
residues K244 and E247 at the opposite pole. This orientation supports the concept that the LRD is tilted forward in its interface with the hinge
region.
doi:10.1371/journal.pone.0031973.g007
Antibody Epitope and TSH Receptor Structure
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31973Therefore, the unrestricted access of M22 for TSHR residue R255
in the crystal structure of the isolated LRD may not occur in the
TSH holoreceptor, providing further support for the concept that
steric hindrance to M22 binding contributes to TSAb activation of
the receptor.
Our findings also provide insight into the mechanism by which
mAb CS-17 suppresses the high constitutive activity of the TSHR.
Previous studies identified LRD residues Y195 [23], N198 andT200
[14], and hinge residues T273 and R274 [14] as contributing to the
CS-17 epitope (Fig. 7). The present observations regarding TSHR
residues K244 and E247, or the intervening loop between these two
residues, support our hypothesis for the mechanism by which CS-17
exerts its inverse agonist activity [14]. Residues K244 and E247 are
further downstream of residues Y195, N198 and T200, almost at the
C-terminal end of the TSHR LRD (Fig. 7). Clearly, therefore, CS-17
binds to the convex dorsum of the LRD adjacent to the hinge region.
These epitopic components, together with hinge residues T273 and
R274 suggest that mAb CS-17 ‘fixes’ the LRD-hinge unit in a manner
that reduces constitutive signaling. Because the TSHR ectodomain is
itself an inverse agonist [30,31], CS-17 may induce an LRD-hinge
orientation that accentuates the intrinsic silencing of the receptor.
In summary, with respect to coupling TSH binding to TSHR
activation, residue E251 is dominant among the five charged
residues at the base of the LRD selected for study. However, when
mutated as a group, other adjacent amino acids, particularly K250
and R255 do, indeed, contribute to coupling TSH binding and
signal transduction. These data support the hypothesis that
multiple amino acids are involved in stabilizing the TSHR
LRD-hinge complex and are involved in transmission of a signal to
the TMD. Most important, the serendipitous finding that the mAb
CS-17 epitope includes LRD residues K244 and E247, near the
dorsal base of the LRD, provides strong evidence that the concave
surface of the LRD is tilted forward towards the membrane,
providing insight into the mechanism by which ligands either
activate the receptor or reduce its constitutive activity.
Methods
TSHR cDNA mutations
Introduction of the wild-type human TSHR (hTSHR) cDNA
[32](with the H601 polymorphism converted to Y601) into the
vector pcDNA5/FRT was described previously [33]. Amino acid
numbering includes the signal peptide. The TSHR cDNA
mutations described below in the text were generated using the
QuikChange site-directed mutagenesis kit (Stratagene, San Diego,
CA). All mutations were confirmed by nucleotide sequencing.
TSHR expression
TSHR cDNAs were transfected into Flp-In-CHO cells (Invitro-
gen) using Fugene HD (Roche, Indianapolis IN). Cell lines stably
expressing the TSHR were obtained by selection with hygromycin
B (Invitrogen; ,300 mg/ml). Cells were cultured in Ham’s F12
medium supplemented with 10% fetal calf serum, penicillin
(100 U/ml), gentamycin (50 mg/ml) and fungizone (2.5 mg/ml).
Cultured cell cAMP assays
CHO cells stably expressing the wild-type or mutated TSHR
were transferred into 96-well plates. For bioassay, the culture
medium described above was replaced with F12 medium
supplemented with 1 mM isobutyl methylxanthine (IBMX),
10 mM HEPES, 0.3% bovine serum albumin and, where
indicated in the text, bovine (b) TSH (Sigma-Aldrich, St. Louis
MO) or M22 [19], kindly provided by Dr. B. Rees-Smith (R.S.R.
Ltd., Cardiff U.K.). Untransfected CHO cells were included as
controls. After 60 min at 37 C, the medium was aspirated and
intracellular cAMP was extracted with 0.2 ml 95% ethanol. The
extracts were evaporated to dryness, resuspended in 0.1 ml of
PBS, pH 7.5, and samples (12 ml) were assayed using the LANCE
cAMP kit according to the protocol of the manufacturer
(PerkinElmer, Shelton CT). The effective dose of TSH required
for half maximal stimulation of intracellular cAMP levels (EC50)
was calculated using GraphPad Prism software (La Jolla, CA).
TSH binding
CHO cells expressing the TSHR were cultured in 24-well
plates. Medium was aspirated and replaced with 250 ml binding
buffer (Hanks’ buffer with 250 mM sucrose substituting for NaCl
to maintain isotonicity and 0.25% bovine serum albumin)
containing ,30,000 cpm
125I-TSH (B.R.A.H.M.S, Berlin Ger-
many) and the indicated concentrations of unlabeled bTSH. After
incubation for 4 h at room temperature, cells were rapidly rinsed
three times with binding buffer (4uC), solubilized with 0.2 ml 1 N
NaOH, and radioactivity was then measured in a c-counter. TSH
binding affinities were measured by Scatchard analysis using
GraphPad Prism (La Jolla, CA), excluding the low affinity, high
capacity non-specific binding site to which TSH (unlike the other
glycoprotein hormone receptors) is susceptible. Non-linear regres-
sion analysis does not provide reliable information in all TSHR
binding experiments.
Flow Cytometry
CHO cells were harvested from 6 well plates using 1 mM
EDTA, 1 mM EGTA in PBS. After washing twice with PBS
containing 10 mM HEPES, pH 7.4, 2% fetal bovine serum, and
0.05% NaN3, the cells were incubated for 30 min at room
temperature in 100 ml of the same buffer containing 1 mg of either
normal mouse IgG or murine mAb 2C11 and 4C1 (Morphosys,
Raleigh NC), as well as mAb CS-17 [16]. After rinsing, the cells
were incubated for 45 min with 100 ml fluorescein isothiocyanate-
conjugated goat anti-mouse IgG (1:100) (Caltag, Burlingame, CA),
washed, and analyzed using a Beckman FACScan flow cyto-
fluorimeter. Cells stained with propidium iodide (1 mg/ml final
concentration) were excluded from analysis.
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